Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 196

1.

The controversial effects of thiazolidinediones on cardiovascular morbidity and mortality.

Stafylas PC, Sarafidis PA, Lasaridis AN.

Int J Cardiol. 2009 Jan 24;131(3):298-304. doi: 10.1016/j.ijcard.2008.06.005. Epub 2008 Aug 5. Review.

PMID:
18684530
2.

PPAR-γ agonism for cardiovascular and renal protection.

Sarafidis PA, Georgianos PI, Lasaridis AN.

Cardiovasc Ther. 2011 Dec;29(6):377-84. doi: 10.1111/j.1755-5922.2010.00222.x. Epub 2010 Sep 15. Review.

PMID:
20840193
3.

Reassessing the cardiovascular risks and benefits of thiazolidinediones.

Zinn A, Felson S, Fisher E, Schwartzbard A.

Clin Cardiol. 2008 Sep;31(9):397-403. doi: 10.1002/clc.20312. Review.

4.

Cardiovascular risk and cardiometabolic protection: role of glitazones.

Petrazzi L, Grassi D, Polidoro L, D'Aurelio A, Croce G, Properzi G, Tiberti S, Desideri G, Ferri C.

J Nephrol. 2008 Nov-Dec;21(6):826-35. Review.

PMID:
19034866
5.
6.

Thiazolidinediones in type 2 diabetes: a cardiology perspective.

Khanderia U, Pop-Busui R, Eagle KA.

Ann Pharmacother. 2008 Oct;42(10):1466-74. doi: 10.1345/aph.1K666. Epub 2008 Sep 2. Review.

PMID:
18698014
7.

The cardiovascular safety of rosiglitazone.

Ajjan RA, Grant PJ.

Expert Opin Drug Saf. 2008 Jul;7(4):367-76. doi: 10.1517/14740338.7.4.367 . Review.

PMID:
18613801
8.

The Clinical Significance of PPAR Gamma Agonism.

Campbell IW.

Curr Mol Med. 2005 May;5(3):349-63. Review.

PMID:
15892654
9.

Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone.

Dahabreh IJ, Economopoulos K.

Clin Trials. 2008;5(2):116-20. doi: 10.1177/1740774508090212. Erratum in: Clin Trials. 2008;5(5):559. Economopoulos, K [added].

PMID:
18375649
10.
11.

Effects of PPAR gamma agonists on cardiovascular function in obese, non-diabetic patients.

Panunti B, Fonseca V.

Vascul Pharmacol. 2006 Jul;45(1):29-35. Epub 2006 Jun 14. Review.

PMID:
16777491
12.

[Heart failure with thiazolidinedione treatment: what do we know today?].

Erdmann E.

Dtsch Med Wochenschr. 2009 Jan;134(4):154-8. doi: 10.1055/s-0028-1123973. Epub 2009 Jan 15. Review. German.

PMID:
19148858
13.

Diabetes and cardiovascular risk markers.

Erdmann E.

Curr Med Res Opin. 2005;21 Suppl 1:S21-8. Review.

PMID:
15811196
14.

Thiazolidinediones: effects on insulin resistance and the cardiovascular system.

Quinn CE, Hamilton PK, Lockhart CJ, McVeigh GE.

Br J Pharmacol. 2008 Feb;153(4):636-45. Epub 2007 Oct 1. Review.

15.

Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus.

Irons BK, Greene RS, Mazzolini TA, Edwards KL, Sleeper RB.

Pharmacotherapy. 2006 Feb;26(2):168-81. Review.

PMID:
16466323
16.

PPARgamma agonists: safety issues in heart failure.

Tang WH, Maroo A.

Diabetes Obes Metab. 2007 Jul;9(4):447-54. Review.

PMID:
17587386
17.

How safe is the use of thiazolidinediones in clinical practice?

Rizos CV, Elisaf MS, Mikhailidis DP, Liberopoulos EN.

Expert Opin Drug Saf. 2009 Jan;8(1):15-32. doi: 10.1517/14740330802597821 . Review.

PMID:
19236215
18.

PPAR- γ agonist in treatment of diabetes: cardiovascular safety considerations.

Abbas A, Blandon J, Rude J, Elfar A, Mukherjee D.

Cardiovasc Hematol Agents Med Chem. 2012 Jun;10(2):124-34. Review.

PMID:
22471957
19.

The safety of rosiglitazone in the treatment of type 2 diabetes.

Singh S, Loke YK.

Expert Opin Drug Saf. 2008 Sep;7(5):579-85. doi: 10.1517/14740338.7.5.579 . Review.

PMID:
18759710
20.

Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials.

Hernandez AV, Usmani A, Rajamanickam A, Moheet A.

Am J Cardiovasc Drugs. 2011;11(2):115-28. doi: 10.2165/11587580-000000000-00000. Review.

PMID:
21294599

Supplemental Content

Support Center